Antibiotics active against Chlamydia do not reduce the risk of myocardial infarction

European Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 43-49

  Bjerrum, Lars ^a   Andersen, Morten ^a   Hallas, Jesper ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Antibiotics; Chlamydia pneumoniae; Myocardial infarction

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BACAMPICILLIN; CIPROFLOXACIN; CLARITHROMYCIN; DICLOXACILLIN; DOXYCYCLINE; ERYTHROMYCIN; FLEROXACIN; FLUCLOXACILLIN; LYMECYCLINE; MACROLIDE; OFLOXACIN; OXYTETRACYCLINE; PENICILLIN V; PIVAMPICILLIN; PIVMECILLINAM; QUINOLONE; ROXITHROMYCIN; TETRACYCLINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATHEROSCLEROSIS; CHLAMYDIA; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EXPOSURE; DRUG USE; FEMALE; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 30844452954     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0059-x     Document Type: Article

References (36)

1. Leinonen M, Saikku P (2002) Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2:11-17
2. Lindholt JS, Fasting H, Henneberg EW, Ostergaard L (1999) A review of Chlamydia pneumoniae and atherosclerosis. Eur J Vasc Endovasc Surg 17:283-289
3. Ngeh J, Anand V, Gupta S (2002) Chlamydia pneumoniae and atherosclerosis - what we know and what we don't. Clin Microbiol Infect 8:2-13
4. Dugan JP, Feuge RR, Burgess DS (2002) Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease. Clin Ther 24:719-735
5. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ (1997) Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96:404-407
6. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B (1999) Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 20:121-127
7. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR et al (2000) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102:1755-1760
8. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C et al (1999) Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 99:1540-1547
9. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S et al (2003) Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 361:809-813
10. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S et al. (2003) Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290:1459-1466
11. Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M et al. (2001) Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial. J Med Assoc Thai 84 (Suppl 3):S669-S675
12. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J et al. (2002) Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 105:1555-1560
13. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J et al. (2002) Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106:1219-1223
14. Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M et al. (2003) Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 107:1253-1259
15. Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C et al (2001) Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357:2085-2089
16. Etminan M, Carleton B, Delaney JA, Padwal R (2004) Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy 24:338-343
17. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H (1999) Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 281:427-431
18. Muhlestein JB (2003) Antibiotic treatment of atherosclerosis. Curr Opin Lipidol 14:605-614
19. Gelfand EV, Cannon CP (2004) Antibiotics for secondary prevention of coronary artery disease: an ACES hypothesis but we need to PROVE IT. Am Heart J 147:202-209
20. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM (2000) Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction. J Infect Dis 181[Suppl 3]:S563-S565
21. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM (1999) Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis 5:281-284
22. Luchsinger JA, Pablos-Mendez A, Knirsch C, Rabinowitz D, Shea S (2002) Relation of antibiotic use to risk of myocardial infarction in the general population. Am J Cardiol 89:18-21
23. Herings RM, Leufkens HG, Vandenbroucke JP (2000) Acute myocardial infarction and prior antibiotic use. JAMA 284: 2998-2999
24. Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44:445-448
25. Danish Medicines Agency (2004) Drug statistics 1994-1999. Copenhagen, Denmark
26. Anonymous (1993) Guidelines for ATC classification. In: Rønning M, Sakshaug S (eds) WHO Collaborating Centre for Drug Statistics Methodology, Oslo
27. WHO Collaborating Centre for Drug Statistics Methodology (1999) ATC index with DDDs annually. WHO, Geneva, Switzerland
28. Stata Press (1999) STATA for Windows. Stata Statistical Software, Texas
29. Nielsen HW, Tuchsen F, Jensen MV (1996) Validity of the diagnosis "essential hypertension" in the National Patient Registry. Ugeskr Laeger 158:163-167
30. Madsen M, Balling H, Eriksen LS (1990) The validity of the diagnosis of acute myocardial infarction in 2 registries: the Heart Registry compared to the National Patient Registry. Ugeskr Laeger 152:308-314
31. Rothman K, Greenland S (1998) Precision and validity in epidemiological studies. In: Rothman K, Greenland S (eds) Modern epidemiology. Lippincott-Raven, Philadelphia, pp 128-129
32. Wedzicha JA, Donaldson GC (2003) Exacerbations of chronic obstructive pulmonary disease. Respir Care 48:1204-1213
33. Welin CL, Rosengren A, Wilhelmsen LW (19896) Social relationships and myocardial infarction: a case-control study. J Cardiovasc Risk 3:183-190
34. Hallqvist J, Lundberg M, Diderichsen F, Ahlbom A (1998) Socioeconomic differences in risk of myocardial infarction 1971-1994 in Sweden: time trends, relative risks and population attributable risks. Int J Epidemiol 27:410-415
35. Bruinsma N, Hutchinson JM, van den Bogaard AE, Giamarellou H, Degener J, Stobberingh EE (2003) Influence of population density on antibiotic resistance. J Antimicrob Chemother 51: 385-390
36. Ostergaard L, Sorensen HT, Lindholt J, Sorensen TE, Pedersen L, Eriksen T et al (2001) Risk of hospitalization for cardiovascular disease after use of macrolides and penicillins: a comparative prospective cohort study. J Infect Dis 183:1625-1630